{"id":757243,"date":"2023-05-10T08:30:48","date_gmt":"2023-05-10T12:30:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/"},"modified":"2023-05-10T08:30:48","modified_gmt":"2023-05-10T12:30:48","slug":"cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/","title":{"rendered":"CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023"},"content":{"rendered":"
\n

NEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 15, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2023 and to provide a business update.<\/p>\n

\n Conference Call Details<\/strong>
\n
To access the live conference call, please dial 844-825-9789 from the U.S. and Canada, or 412-317-5180 internationally, Conference ID # 10178303. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company’s website at http:\/\/ir.cymabay.com\/events<\/u><\/a>.<\/p>\n

\n About CymaBay <\/strong>\n <\/p>\n

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class investigational treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit\u00a0www.cymabay.com<\/u><\/a> and follow us on Twitter<\/u><\/a> and Linkedin<\/u><\/a>.<\/p>\n

\n Public Relations Contact<\/strong>
\n :<\/strong>\n <\/p>\n

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com<\/u><\/a><\/p>\n

\n Investor Relations Contact:<\/strong>\n <\/p>\n

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com<\/u><\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 15, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2023 and to provide a business update. Conference Call Details To access the live conference call, please dial 844-825-9789 from the U.S. and Canada, or 412-317-5180 internationally, Conference ID # 10178303. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company’s website at http:\/\/ir.cymabay.com\/events. About … <\/p>\n

Continue reading “CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-757243","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 15, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2023 and to provide a business update. Conference Call Details To access the live conference call, please dial 844-825-9789 from the U.S. and Canada, or 412-317-5180 internationally, Conference ID # 10178303. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company’s website at http:\/\/ir.cymabay.com\/events. About … Continue reading "CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-10T12:30:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTgzOCM1NTg1ODU2IzIwMjgzMzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023\",\"datePublished\":\"2023-05-10T12:30:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\\\/\"},\"wordCount\":286,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTgzOCM1NTg1ODU2IzIwMjgzMzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\\\/\",\"name\":\"CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTgzOCM1NTg1ODU2IzIwMjgzMzk=\",\"datePublished\":\"2023-05-10T12:30:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTgzOCM1NTg1ODU2IzIwMjgzMzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTgzOCM1NTg1ODU2IzIwMjgzMzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/","og_locale":"en_US","og_type":"article","og_title":"CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023 - Market Newsdesk","og_description":"NEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 15, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2023 and to provide a business update. Conference Call Details To access the live conference call, please dial 844-825-9789 from the U.S. and Canada, or 412-317-5180 internationally, Conference ID # 10178303. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company’s website at http:\/\/ir.cymabay.com\/events. About … Continue reading \"CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-10T12:30:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTgzOCM1NTg1ODU2IzIwMjgzMzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023","datePublished":"2023-05-10T12:30:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/"},"wordCount":286,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTgzOCM1NTg1ODU2IzIwMjgzMzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/","name":"CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTgzOCM1NTg1ODU2IzIwMjgzMzk=","datePublished":"2023-05-10T12:30:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTgzOCM1NTg1ODU2IzIwMjgzMzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTgzOCM1NTg1ODU2IzIwMjgzMzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-first-quarter-of-2023-financial-results-on-monday-may-15-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/757243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=757243"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/757243\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=757243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=757243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=757243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}